[Effects of metabolic substrates and mannitol on efficiency of cardioplegic protection in isolated rat heart].
The aim of this work was to study rationality of addition of aspartic acid, phosphocreatine, mannitol and tris(bydroxymethyl) aminomethane (trisamine) to a sanguineous cardioplegic solution. Isolated perfused rat hearts were subjected to 40-min normothermic total ischemia and 30-min reperfusion. Cardioplegic solutions were infused for 5 min prior to ischemia. A modified Ringer solution with 25 mM KCI was used as control. Osmolarity and pH of cardioplegic solutions were 340+/-5 mOms and 7.6+/-0.1 at 22 degreesC, respectively. Efficiency of myocardial protection was evaluated by recovery of contractile and pump function during reperfusion. The optimal solution contained aspartic acid (21.5 mM), mannitol (20.0 mM) and trisamine (5 mM). By the end of reperfusion the heart protected by this solution showed almost complete recovery of coronary flow (98+/-3% of the initial value vs. 77+/-3% in the control), and 2.6-fold higher recovery of stroke volume compared to the control. As a result, recovery of external cardiac work index, calculated as cardiac output-mean perfusion pressure, was 64+/-1% of the initial value vs. 24+/-5% in the control. Increase in buffer capacity of this cardioplegic solution by trisamine (up to 20.0 mM) as well as addition of phosphocreatine (10.0 mM) did not result in further augmentation of cardiac function recovery. The results suggest promising perspectives for development of medicinal form of this solution.
Pisarenko
O I
OI
Shul'zhenko
V S
VS
Studneva
I M
IM
Lepilin
M G
MG
D000818:Animals; D001224:Aspartic Acid / Q000008:administration & dosage / Q000032:analysis* / Q000494:pharmacology*; D002314:Cardioplegic Solutions / Q000737:chemistry*; D003971:Diastole / Q000187:drug effects; D004234:Diuretics, Osmotic / Q000008:administration & dosage / Q000032:analysis* / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000032:analysis* / Q000494:pharmacology*; D008744:Methylamines / Q000008:administration & dosage / Q000032:analysis* / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000517:prevention & control; D010725:Phosphocreatine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013599:Systole / Q000187:drug effects
D002314:Cardioplegic Solutions; D004234:Diuretics, Osmotic; D008744:Methylamines; D010725:Phosphocreatine; D001224:Aspartic Acid; D008353:Mannitol; C025403:phosphocreatinine; C027451:methylamine